Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

Author： Norman Peter  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.24, Iss.5, 2014-05, pp. : 573-595

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

β-Lactamase inhibitors: a review of the patent literature (2010 – 2013)

By Buynak John D  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 11, 2013-11 ,pp. : 1469-1481

Informa Healthcare

Access to resources Recommend Favorite

Checkpoint kinase inhibitors: a patent review (2009 –– 2010)

By Lainchbury Michael   Collins Ian  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 8, 2011-08 ,pp. : 1191-1210

Informa Healthcare

Access to resources Recommend Favorite

Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature

By Dai Yujia  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 7, 2010-07 ,pp. : 885-897

Informa Healthcare

Access to resources Recommend Favorite

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

By Moore William J   Richard David   Thorarensen Atli  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1703-1722

Informa Healthcare

Access to resources Recommend Favorite

FMS-like tyrosine kinase 3 inhibitors: a patent review

By Lee Jongkook   Paek Seung-Mann   Han Sun-Young  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 4, 2011-04 ,pp. : 483-503

Informa Healthcare

Access to resources Recommend Favorite